Atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) is an indolent, locally aggressive mesenchymal neoplasm, most often confined to the lower extremities and retroperitoneum and rarely identified in the orbit. Diagnosis of ALT/WDL can be challenging due to its frequent morphologic overlap with benign adipose lesions and other more aggressive liposarcoma subtypes, including myxoid liposarcoma. We describe a 26-year-old female with a history of hereditary retinoblastoma and external-beam radiotherapy to the orbit, who developed orbital liposarcoma. Although initial morphologic assessment raised the consideration of myxoid liposarcoma, subsequent fluorescein in situ hybridization studies demonstrated MDM2 and DDIT3 coamplification without DDIT3 rearrangement, supporting the diagnosis of ALT/WDL with myxoid stroma. The literature review of previously reported orbital myxoid liposarcomas revealed a morphologic overlap of documented tumors with ALT/WDL, dedifferentiated liposarcoma, and pleomorphic liposarcoma with myxoid stroma as well as an absence of immunohistochemical and molecular genetic data supportive of the diagnosis of myxoid liposarcoma. This case emphasizes the potential overlap of ALT/WDL with myxoid liposarcoma and the increasing importance of molecular genetic studies in the diagnosis, prognosis, and management of orbital liposarcoma.

1.
Madge
SN
,
Tumuluri
K
,
Strianese
D
,
Bonavolonta
P
,
Wilcsek
G
,
Dodd
TJ
, et al.
Primary orbital liposarcoma
.
Ophthalmology
.
2010
Mar
;
117
(
3
):
606
14
.
[PubMed]
0161-6420
2.
Fletcher
CD
,
Hogendoorn
P
,
Mertens
F
.
WHO Classification of Tumours of Soft Tissue and Bone
. 4th edition, revised.
Lyon
:
IARC Press
;
2013
.
3.
Dei Tos
AP
.
Liposarcomas: diagnostic pitfalls and new insights
.
Histopathology
.
2014
Jan
;
64
(
1
):
38
52
.
[PubMed]
0309-0167
4.
Sioletic
S
,
Dal Cin
P
,
Fletcher
CD
,
Hornick
JL
.
Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases
.
Histopathology
.
2013
Jan
;
62
(
2
):
287
93
.
[PubMed]
0309-0167
5.
McKey
K
,
Zhang
PJ
,
Shields
CL
,
Lally
SE
,
Eagle
RC
 Jr
,
Milman
T
.
Orbital Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma Masquerading as Pleomorphic Lipoma: A Diagnostic Challenge
.
Ophthal Plast Reconstr Surg
.
2019
Mar
;
35
(
3
):
e76
80
.
[PubMed]
0740-9303
6.
Mantilla
JG
,
Ricciotti
RW
,
Chen
EY
,
Liu
YJ
,
Hoch
BL
.
Amplification of DNA damage-inducible transcript 3 (DDIT3) is associated with myxoid liposarcoma-like morphology and homologous lipoblastic differentiation in dedifferentiated liposarcoma
.
Mod Pathol
.
2019
Apr
;
32
(
4
):
585
92
.
[PubMed]
0893-3952
7.
Cai
YC
,
McMenamin
ME
,
Rose
G
,
Sandy
CJ
,
Cree
IA
,
Fletcher
CD
.
Primary liposarcoma of the orbit: a clinicopathologic study of seven cases
.
Ann Diagn Pathol
.
2001
Oct
;
5
(
5
):
255
66
.
[PubMed]
1092-9134
8.
Lane
CM
,
Wright
JE
,
Garner
A
.
Primary myxoid liposarcoma of the orbit
.
Br J Ophthalmol
.
1988
Dec
;
72
(
12
):
912
7
.
[PubMed]
0007-1161
9.
Blodi
FC
.
Unusual orbital neoplasms
.
Am J Ophthalmol
.
1969
Sep
;
68
(
3
):
407
12
.
[PubMed]
0002-9394
10.
Naeser
P
,
Moström
U
.
Liposarcoma of the orbit: a clinicopathological case report
.
Br J Ophthalmol
.
1982
Mar
;
66
(
3
):
190
3
.
[PubMed]
0007-1161
11.
Malan
P
,
Baldet
P
,
Arnaud
B
.
Primary orbital liposarcoma: clinicopathologic case report and review of the literature
.
Orbit
.
1983
;
2
(
2
):
99
105
. 0167-6830
12.
Jakobiec
FA
,
Rini
F
,
Char
D
,
Orcutt
J
,
Rootman
J
,
Baylis
H
, et al.
Primary liposarcoma of the orbit. Problems in the diagnosis and management of five cases
.
Ophthalmology
.
1989
Feb
;
96
(
2
):
180
91
.
[PubMed]
0161-6420
13.
McNab
AA
,
Moseley
I
.
Primary orbital liposarcoma: clinical and computed tomographic features
.
Br J Ophthalmol
.
1990
Jul
;
74
(
7
):
437
9
.
[PubMed]
0007-1161
14.
Favrot
SR
,
Ridley
MB
,
Older
JJ
,
Szakacs
JE
.
Orbital liposarcoma
.
Otolaryngol Head Neck Surg
.
1994
Jul
;
111
(
1
):
111
5
.
[PubMed]
0194-5998
15.
Sabb
PC
,
Syed
NA
,
Sires
BS
,
Lemke
BN
,
Dortzbach
RK
,
Albert
DM
.
Primary orbital myxoid liposarcoma presenting as orbital pain
.
Arch Ophthalmol
.
1996
Mar
;
114
(
3
):
353
4
.
[PubMed]
0003-9950
16.
Cockerham
KP
,
Kennerdell
JS
,
Celin
SE
,
Fechter
HP
.
Liposarcoma of the orbit: a management challenge
.
Ophthal Plast Reconstr Surg
.
1998
Sep
;
14
(
5
):
370
4
.
[PubMed]
0740-9303
17.
Wagle
AM
,
Biswas
J
,
Subramaniam
N
,
Mahesh
L
.
Primary liposarcoma of the orbit: a clinicopathological study
.
Orbit
.
1999
Mar
;
18
(
1
):
33
6
.
[PubMed]
0167-6830
18.
Al-Qahtani
AA
,
Al-Hussain
H
,
Chaudhry
I
,
El-Khamary
S
,
Alkatan
HM
.
Primary orbital liposarcoma: histopathologic report of two cases
.
Middle East Afr J Ophthalmol
.
2011
Oct
;
18
(
4
):
314
6
.
[PubMed]
0974-9233
19.
Khurana
S
,
Gupta
AK
,
Sen
S
,
Kashyap
S
.
Primary liposarcoma of the orbit
.
Indian J Pathol Microbiol
.
2014
Oct-Dec
;
57
(
4
):
617
9
.
[PubMed]
0377-4929
20.
Muratori
F
,
Bettini
L
,
Frenos
F
,
Mondanelli
N
,
Greto
D
,
Livi
L
, et al.
Myxoid Liposarcoma: Prognostic Factors and Metastatic Pattern in a Series of 148 Patients Treated at a Single Institution
.
Int J Surg Oncol
.
2018
May
;
2018
:
8928706
.
[PubMed]
2090-1402
21.
Nassif
NA
,
Tseng
W
,
Borges
C
,
Chen
P
,
Eisenberg
B
.
Recent advances in the management of liposarcoma
.
[version 1;referees: 2 approved]
.
F1000 Res
.
2016
Dec
;
5
:
2907
.
[PubMed]
2046-1402
22.
Trautmann
M
,
Menzel
J
,
Bertling
C
,
Cyra
M
,
Isfort
I
,
Steinestel
K
, et al.
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma
.
Clin Cancer Res
.
2017
Oct
;
23
(
20
):
6227
38
.
[PubMed]
1078-0432
23.
Kleinerman
RA
,
Tucker
MA
,
Abramson
DH
,
Seddon
JM
,
Tarone
RE
,
Fraumeni
JF
 Jr
.
Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma
.
J Natl Cancer Inst
.
2007
Jan
;
99
(
1
):
24
31
.
[PubMed]
0027-8874
24.
Chaussade
A
,
Millot
G
,
Wells
C
,
Brisse
H
,
Laé
M
,
Savignoni
A
, et al.
Correlation between RB1germline mutations and second primary malignancies in hereditary retinoblastoma patients treated with external beam radiotherapy
.
Eur J Med Genet
.
2019
Mar
;
62
(
3
):
217
23
.
[PubMed]
1769-7212
25.
Dommering
CJ
,
Marees
T
,
van der Hout
AH
,
Imhof
SM
,
Meijers-Heijboer
H
,
Ringens
PJ
, et al.
RB1 mutations and second primary malignancies after hereditary retinoblastoma
.
Fam Cancer
.
2012
Jun
;
11
(
2
):
225
33
.
[PubMed]
1389-9600
26.
Stiglmayer
N
,
Jandrokovicć
S
,
Miklicć
P
,
Hutinec
Z
.
Atypical lipoma: well-differentiated liposarcoma of the orbit with dedifferentiated areas
.
Orbit
.
2003
Dec
;
22
(
4
):
311
6
.
[PubMed]
0167-6830
27.
Rosner
M
,
Yosepovich
A
,
Paul
M
,
Rosen
N
,
Perelman
M
.
Orbital well-differentiated liposarcoma demonstrating chromosomal imbalances
.
Eye (Lond)
.
2006
Jan
;
20
(
1
):
126
8
.
[PubMed]
0950-222X
28.
Jakobiec
FA
,
Nguyen
J
,
Bhat
P
,
Fay
A
.
MDM2-positive atypical lipomatous neoplasm/well-differentiated liposarcoma versus spindle cell lipoma of the orbit
.
Ophthal Plast Reconstr Surg
.
2010
Nov-Dec
;
26
(
6
):
413
5
.
[PubMed]
0740-9303
29.
Torrado
CS
,
Zaldibar
NM
,
Velasco-Benito
V
,
Fernández-Hermida
R
.
Primary orbital liposarcoma
.
J Craniofac Surg
.
2011
May
;
22
(
3
):
1139
41
.
[PubMed]
1049-2275
30.
Vrcek
I
,
Hogan
RN
,
Gilliland
G
.
Orbital liposarcoma masquerading as a hemangioma
.
Proc Bayl Univ Med Cent
.
2014
Oct
;
27
(
4
):
359
60
.
[PubMed]
0899-8280
31.
Dworak
DP
,
Patel
SA
,
Chennuri
R
,
Falco
D
.
Primary Atypical Lipomatous Tumor of the Orbit: A Case Report
.
J Ophthalmic Vis Res
.
2018
Jan-Mar
;
13
(
1
):
78
80
.
[PubMed]
2008-2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.